-
China Medical System’s Opzelura Approved in Hong Kong for Non-segmental Vitiligo Treatment
•
China Medical System Holdings (CMS; HKG: 0867) has announced that the market filing for its Opzelura (ruxolitinib) cream has been approved in Hong Kong. This topical Janus kinase (JAK) inhibitor is now approved for use as a local treatment for non-segmental vitiligo in patients aged 12 years and above, expanding…
-
China Medical System’s Opzelura Cream Filing for Vitiligo Accepted by NMPA
•
China Medical System Holdings (CMS; HKG: 0867) has announced that its market filing for Opzelura (ruxolitinib) cream for the treatment of vitiligo has been accepted for review by the National Medical Products Administration (NMPA). Opzelura is a topical Janus kinase (JAK) inhibitor designed for external use. It received approval in…
-
China Medical System’s Opzelura Approved in Macau for Vitiligo Treatment
•
China Medical System Holdings (CMS; HKG: 0867) has announced that it has received market approval in Macau for Opzelura (ruxolitinib) cream, a topical treatment indicated for patients aged 12 and above with non-segmental vitiligo involving the face. Opzelura, a topical Janus kinase (JAK) inhibitor, was initially approved in the U.S.…
-
China Medical System Expands Portfolio with Incyte’s Povorcitinib for Autoimmune Diseases
•
China Medical System Holdings (CMS; HKG: 0867) has announced a new cooperation and licensing agreement with US-based Incyte Pharmaceuticals Inc. (NSDQ: INCY), focusing on Incyte’s selective oral JAK1 inhibitor, povorcitinib. CMS has secured the exclusive rights to research, develop, file for regulatory approval, and commercialize the drug in Greater China,…
